ROGER CHAMMAS
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
19 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 19
- Melatonin treatment: A transcriptomic networks in a xenograft model of breast cancer(2017) JARDIM-PERASSI, B. V.; SONEHARA, N. M.; PAULA-JUNIOR, R. de; CHAMMAS, R.; COUTINHO, L. L.; REIS JUNIOR, O.; ALEXANDRE, P. A.; FUKUMASU, H.; ZUCCARI, D. A. P. C.
bookPart Bases da biologia molecular(2017) MAZZOTTI, Tatiane Katsue Furuya; LEAL, Mariana Ferreira; CIRILO, Priscila Daniele Ramos; CHAMMAS, Roger- Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy(2017) SILVA JR., I. A. da; CHAMMAS, R.; LEPIQUE, A. P.; JANCAR, S.A major drawback of radiotherapy is the accelerated growth of the surviving tumor cells. Radiotherapy generates a variety of lipids that bind to the receptor for platelet-activating factor, expressed by cells in the tumor microenvironment. In the present study, using the TC-1 tumor cell line, we found that irradiation induced a twofold increase in receptor expression and generated agonists of receptor. Irradiated cells induced a 20-fold increase in live TC-1 proliferation in vitro. Furthermore, subcutaneous co-injection of irradiated TC-1 cells with TC-1 expressing luciferase (TC-1 fluc(+)) markedly increased TC-1 fluc(+) proliferation in a receptor-dependent way. Moreover we used a human carcinoma cell line not expressing the PAF receptor (KBM) and the same cell transfected with the receptor gene (KBP). Following co-injection of live KBP cells with irradiated KBM in RAG mice, the tumor growth was significantly increased compared with tumor formed following co-injection of live KBM with irradiated KBM. This tumor cell repopulation correlated with increased infiltration of tumor-promoting macrophages (CD206+). We propose that receptor represents a possible target for improving the efficacy of radiotherapy through inhibition of tumor repopulation.
- Lu-177-DOTA- Bevacizumab: Radioimmunotherapy Agent for Melanoma(2017) CAMACHO, Ximena; CALZADA, Victoria; FERNANDEZ, Marcelo; ALONSO, Omar; CHAMMAS, Roger; RIVA, Eloisa; GAMBINI, Juan Pablo; CABRAL, PabloBackground: Vascular endothelial growth factor (VEGF) is one of the classic factors to tumor-induced angiogenesis in several types, including melanoma. Bevacizumab is a humanized monoclonal antibody directed against VEGF. Objective: To radiolabel Bevacizumab with 177-Lutetium as a potential radioimmunotherapy agent for melanoma. Methods: Bevacizumab was derivatized with DOTA-NHS-ester at 4 degrees C for 18 h. DOTA-Bevacizumab was radiolabeled with (LuCl3)-Lu-177 (15 MBq/mg) at 37 degrees C for 1 h. The studies were performed in healthy and B16F1 tumor-bearing C57BL/6J mice at 24 and 48 h (n = 5). Scinthigraphic imaging studies were performed at 24 h to determine the radiochemical stability, targeting specificity and pharmacokinetics of the 177Lutetium-labeled antibody. Results: DOTA-Bevacizumab was efficiently labeled with (LuCl3)-Lu-177 at 37 degrees C. The in-vitro stability of labeled product was optimal over 72 h. In-vivo biodistribution studies showed a high liver and tumor uptake of Lu-177-DOTA-Bevacizumab, with tumor-to-muscle ratios of 11.58 and 6.37 at 24 and 48 h p.i. Scintigraphic imaging of melanoma tumor-bearing C57BL/6J mice showed liver and a high tumor selective uptake of Lu-177-DOTA-Bevacizumab at 24 h. Conclusions: Our results support the potential role of Lu-177-DOTA-Bevacizumab as a novel radioimmunotherapy agent for melanoma. We hope that these novel molecular imaging agents will open the path to new diagnostic and therapeutic strategies for Melanoma disease.
- Tocilizumab Labeling with (99m)Technetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma(2017) CAMACHO, Ximena; MACHADO, Camila Longo; GARCIA, Maria Fernanda; FERNANDEZ, Marcelo; ODDONE, Natalia; BENECH, Juan; GAMBINI, Juan Pablo; CERECETTO, Hugo; CHAMMAS, Roger; CABRALA, Pablo; RIVA, EloisaBackground: Multiple myeloma is the second most common hematological malignancy. Interleukin-6 (IL-6) is one of the key molecules related to growth, survival and proliferation of myeloma cells. Tocilizumab is a humanized monoclonal antibody directed against receptor of IL-6. Objective: To radiolabel Tocilizumab with (99m)Technetium as a potential imaging agents for MM. Methods: IL-6R expression was studied by laser confocal microscopy in MM cell lines (U266, NCI-H929 and MM1S). Tocilizumab was derivatized with NHS-HYNIC-Tfa and radiolabeling with Tc-99m. Radiochemical stability was determined. In-vitro binding and immunoreactive fraction assays were performed. Biodistribution and SPECT/CT imaging were evaluated in healthy BALB/c and MM-bearing BALB/c nude mice. Results: LCM studies allowed us to demonstrate that U266, NCI-H929 and MM1S cells present high expression of IL-6R in cell membrane. Radiolabeling was carried out in a fast, reproducible, easy and stable way having high radiochemical purity and did not interfere with epitope recognition. The immunoreactive fraction of (TcHYNIC)-Tc-99m-Tocilizumab was 86.35%. Biodistribution showed a high uptake in liver, spleen, gastrointestinal tract and kidneys. SPECT/CT imaging of MM-bearing BALB/c nude mice showed liver uptake and a high tumor selective uptake at 24 hours. Conclusions: Our results support the potential role of 99mTc-HYNIC-Tocilizumb as a novel MM radiotracer for targeting IL-6 expression in-vivo. We describe the development of a formulation kit to radiolabeling monoclonal antibodies in a clinical setting. We hope that these novel molecular imaging agents will open the path to new diagnostic and therapeutic strategies for MM disease.
conferenceObject Near Infrared Fluorescence In-Vivo Imaging of Non-Hodgkin Lymphoma Using Cy7-Bevacizumab(2017) CAMACHO, Ximena; PERRONI, Carolina; JUNQUEIRA, Mara de Souza; FERNANDEZ, Marcelo; BUSTOS, Silvina; BUCHPIGUEL, Carlos; CHAMMAS, Roger; GAMBINI, Juan Pablo; CABRAL, Pablo; RIVA, Eloisa- Safe therapeutics of murine melanoma model using a novel antineoplasic, the partially methylated mannogalactan from Pleurotus eryngii(2017) BISCAIA, S. M. P.; CARBONERO, E. R.; BELLAN, D. L.; BORGES, B. S.; COSTA, C. R.; ROSSI, G. R.; GONCALVES, J. P.; MELO, C. M.; LIVERO, F. A. R.; RUTHES, A. C.; ZOTZ, R.; SILVA, E. V.; OLIVEIRA, C. C.; ACCO, A.; NADER, H. B.; CHAMMAS, R.; IACOMINI, M.; FRANCO, C. R. C.; TRINDADE, E. S.A heteropolysaccharide was isolated by cold aqueous extraction from edible mushroom Pleurotus eryngii (""King Oyster"") basidiocarps and its biological properties were evaluated. Structural assignments were carried out using mono-and bidimensional NMR spectroscopy, monosaccharide composition, and methylation analyses. A man-nogalactan having a main chain of (1 -> 6)-linked alpha-D-galactopyranosyl and 3-O-methyl-alpha-D-galactopyranosyl residues, both partially substituted at OH-2 by beta-D-Manp (MG-Pe) single-unit was found. Biological effects of mannogalactan from P. eryngii (MG-Pe) were tested against murine melanoma cells. MG-Pe was non-cytotoxic, but reduced in vitro melanoma cells invasion. Also, 50 mg/kg MG-Pe administration to melanoma-bearing C57BL/6 mice up to 10 days decreased in 60% the tumor volume compared to control. Additionally, no changes were observed when biochemical profile, complete blood cells count (CBC), organs, and body weight were analyzed. Mg-Pe was shown to be a promising anti-melanoma molecule capable of switching melanoma cells to a non-invasive phenotype with no toxicity to melanoma-bearing mice.
article 12 Citação(ões) na Scopus Oncogenic effects of PAFR ligands produced in tumours upon chemotherapy and radiotherapy(2017) CHAMMAS, Roger; ANDRADE, Luciana Nogueira de Sousa; JANCAR, SoniabookPart Biobancos(2017) UNO, Miyuki; CHAMMAS, Roger- Avaliação de aplicação única subconjuntival pré-operatória de mitomicina C em pterígio primário(2017) MARTINS, Thiago Gonçalves dos Santos; COSTA, Ana Luiza Fontes de Azevedo; FURUZAWA, Karina Mie; ALVES, Milton Ruiz; CHAMMAS, RogerAbstract Pterygia are usually benign lesions that do not require specific treatment. It is a fibrovascular growth onto the nasal side of the cornea. It`s cause has not been fully elucidated yet, but seems to be related to long -term ultraviolet ray exposure. When symptoms are not controlled with conservative treatment surgery is considered, but the recurrence rate is still high, and efforts have been made to avoid it. Mitomycin C (MMC) is a fibroblast proliferation inhibitor that can be used as adjuvant to surgery to reduce recurrence. We report here a case that describes pterygium surgery performed in both eyes of the same patient, being one with MMC and the other eye without it. Both pterygium were sent to laboratory analysis. The results and proliferation index were compared between the eyes.